297 related articles for article (PubMed ID: 18423779)
1. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
2. Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
Kundranda MN; Niu J
Drug Des Devel Ther; 2015; 9():3767-77. PubMed ID: 26244011
[TBL] [Abstract][Full Text] [Related]
3. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies.
Loong HH; Chan AC; Wong AC
J Cancer; 2016; 7(3):268-75. PubMed ID: 26918039
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.
Dranitsaris G; Yu B; King J; Kaura S; Zhang A
Clinicoecon Outcomes Res; 2015; 7():249-56. PubMed ID: 25999749
[TBL] [Abstract][Full Text] [Related]
5. Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles.
Kianfar E
J Nanobiotechnology; 2021 May; 19(1):159. PubMed ID: 34051806
[TBL] [Abstract][Full Text] [Related]
6. Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas.
Tian Z; Yao W
Front Oncol; 2022; 12():815900. PubMed ID: 35223497
[TBL] [Abstract][Full Text] [Related]
7. Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel.
Huang JW; Kuo CH; Kuo HC; Shih JY; Tsai TW; Chang LC
PLoS One; 2021; 16(3):e0248942. PubMed ID: 33740022
[TBL] [Abstract][Full Text] [Related]
8. Differences in Fatty Acid Oxidation between
Huang JW; Kuo CH; Kuo HC; Shih JY; Tsai TW; Chang LC
ACS Omega; 2021 Mar; 6(8):5138-5145. PubMed ID: 33681555
[TBL] [Abstract][Full Text] [Related]
9. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
Kratz F
J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
Fu Q; Sun J; Zhang W; Sui X; Yan Z; He Z
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):262-72. PubMed ID: 19538176
[TBL] [Abstract][Full Text] [Related]
11. Albumin-based nanoparticles as potential controlled release drug delivery systems.
Elzoghby AO; Samy WM; Elgindy NA
J Control Release; 2012 Jan; 157(2):168-82. PubMed ID: 21839127
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
13. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
14. Impact of albumin on drug delivery--new applications on the horizon.
Elsadek B; Kratz F
J Control Release; 2012 Jan; 157(1):4-28. PubMed ID: 21959118
[TBL] [Abstract][Full Text] [Related]
15. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
Guarneri V; Dieci MV; Conte P
Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
[TBL] [Abstract][Full Text] [Related]
16. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.
Miele E; Spinelli GP; Miele E; Tomao F; Tomao S
Int J Nanomedicine; 2009; 4():99-105. PubMed ID: 19516888
[TBL] [Abstract][Full Text] [Related]
17. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling.
Dave B; Granados-Principal S; Zhu R; Benz S; Rabizadeh S; Soon-Shiong P; Yu KD; Shao Z; Li X; Gilcrease M; Lai Z; Chen Y; Huang TH; Shen H; Liu X; Ferrari M; Zhan M; Wong ST; Kumaraswami M; Mittal V; Chen X; Gross SS; Chang JC
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8838-43. PubMed ID: 24876273
[TBL] [Abstract][Full Text] [Related]
18. Delivering nanomedicine to solid tumors.
Jain RK; Stylianopoulos T
Nat Rev Clin Oncol; 2010 Nov; 7(11):653-64. PubMed ID: 20838415
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
